Correction: Corrigendum: EPPS rescues hippocampus-dependent cognitive deficits in APP/PS1 mice by disaggregation of amyloid-β oligomers and plaques

Hye Yun Kim, Hyunjin Vincent Kim, Seonmi Jo, C. Justin Lee, Seon Young Choi, Dong Jin Kim, Young Soo KimNature Communications 2016 · DOI · OpenAlex

Abstract

This report summarizes the therapeutic potential of EPPS (4-(2-hydroxyethyl)-1-piperazinepropanesulfonic acid) in reversing Alzheimer’s-like pathology, as detailed in Nature Communications and its subsequent corrigendum. The research identifies EPPS as a small molecule capable of penetrating the blood-brain barrier to physically dismantle amyloid-β (Aβ) aggregates. In an APP/PS1 mouse model, oral administration of EPPS led to the clearance of plaques and toxic oligomers, which in turn restored hippocampal Long-Term Potentiation (LTP) and rescued cognitive performance. These findings suggest that reversing established Aβ pathology is a viable therapeutic strategy for Alzheimer’s disease.

Introduction: Targeting Established Pathology

The "Amyloid Cascade Hypothesis" identifies the accumulation of amyloid-β (Aβ) as a central driver of Alzheimer’s Disease (AD). While preventative strategies have seen limited success, this study investigates the feasibility of disaggregating existing, stable Aβ plaques and toxic oligomers. Using the APP/PS1 mouse model, researchers tested whether the small molecule EPPS could physically dismantle these aggregates and if such "cleanup" would allow for the recovery of neural function.

Methods

The researchers administered EPPS orally to APP/PS1 transgenic (TG) mice and Wild Type (WT) controls. The impact was assessed through three primary lenses:

  • Electrophysiology: Long-Term Potentiation (LTP) was measured by recording field excitatory postsynaptic potentials (fEPSP) in hippocampal slices to evaluate synaptic plasticity.
  • Histology: Amyloid plaque density and area were quantified in the hippocampus and cortex using Thioflavin S (ThS) staining.
  • Biochemistry: Soluble monomers, toxic oligomers, and insoluble Aβ aggregates were quantified via Western blotting and ELISA.

Key Results: Functional Recovery of Synaptic Plasticity

The most significant finding is the restoration of hippocampal LTP in symptomatic mice. As shown in the corrected Figure 3, untreated TG mice exhibit severely impaired LTP. However, TG mice treated with EPPS (EPPS++/TG) showed a full rescue of synaptic potentiation, with fEPSP slopes reaching levels comparable to WT controls. This indicates that the neural circuitry remains capable of plasticity once the Aβ burden is reduced.

Figure 3: Electrophysiological recordings demonstrating that EPPS treatment restores LTP in transgenic (TG) mice. Panels a-d show baseline and post-TBS fEPSP slopes for WT mice. Panels e-h show the corresponding data for TG mice, where EPPS treatment (blue) significantly improves potentiation compared to untreated TG mice (black), as summarized in the bar graph (panel h).

Plaque Clearance and Oligomer Reduction

Histological and biochemical analyses confirmed that the functional recovery was driven by a massive reduction in plaque load. EPPS treatment led to a dose-dependent decrease in both the number of plaques and the total area occupied by Aβ in the brain. Crucially, EPPS also reduced the levels of toxic, high-molecular-weight oligomers, which are widely considered the most damaging Aβ species to synaptic health.

Discussion and Clinical Outlook

The ability of EPPS to act as a "molecular crowbar" and dismantle stable Aβ aggregates represents a significant shift in AD research, moving from prevention to potential reversal. However, translating these results to human patients involves several hurdles:

  • Disease Stage: Human AD pathology develops over decades; the efficacy of disaggregation in late-stage human disease remains to be seen.
  • Debris Clearance: While EPPS breaks down plaques, the mechanisms by which the brain clears the resulting protein fragments (e.g., microglial activity) require further study.
  • Safety and Metabolism: The long-term safety profile of EPPS in humans must be established through clinical trials.

In conclusion, this study highlights the brain's remarkable capacity for functional recovery and identifies Aβ disaggregation as a promising therapeutic avenue.

Summary updated

Abstract

Nature Communications 6: Article number: 8997 (2015); Published: 8 December 2015; Updated: 15 February 2016 This Article contains errors in Figs 3 and 4. In Fig. 3h, the x axis should have been labelled ‘TG’, and in Fig. 4a, labels denoting the EPPS dose for each image were inadvertently removed. The correct versions of these two figures follow.
BibTeX
@inproceedings{kim2016correction,
  author = {Hye Yun Kim and Hyunjin Vincent Kim and Seonmi Jo and C. Justin Lee and Seon Young Choi and Dong Jin Kim and Young Soo Kim},
  title = {{Correction: Corrigendum: EPPS rescues hippocampus-dependent cognitive deficits in APP/PS1 mice by disaggregation of amyloid-β oligomers and plaques}},
  booktitle = {Nature Communications},
  year = {2016},
  doi = {10.1038/ncomms10755},
}
Figure